Comparative Pharmacology
Head-to-head clinical analysis: FYLNETRA versus GRANIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FYLNETRA versus GRANIX.
FYLNETRA vs GRANIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FYLNETRA (filgrastim-ayow) is a granulocyte colony-stimulating factor (G-CSF) analog that binds to the G-CSF receptor on neutrophils and their precursors, stimulating proliferation, differentiation, and functional activation of neutrophils.
Granix (tbo-filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog that binds to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
3.6 mg/kg subcutaneously once daily for up to 14 days. Dose based on absolute neutrophil count.
5 μg/kg subcutaneously once daily for up to 7 days, or 5 μg/kg subcutaneously once daily for up to 14 days for stem cell mobilization.
None Documented
None Documented
Terminal elimination half-life approximately 3.5 hours (range 2–5 hours); supports daily dosing in most patients for myelosuppressive chemotherapy.
Terminal half-life approximately 3.5 hours (range 1.8–5.4 h) in healthy subjects; clearance increases with neutrophil recovery due to G-CSF receptor-mediated uptake.
Renal (primarily, as unchanged drug and metabolites, minor biliary/fecal)
Primarily renal excretion; neutrophil-mediated clearance. <1% unchanged in urine.
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor